Comparison of eptifibatide and abciximab with decision analysis.
Wong
D H
DH
Department of Pharmacy Services, Methodist Hospital of Southern California, 300 West Huntington Drive, Arcadia, CA 91007, USA.
D000077284:Abciximab; D000328:Adult; D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D002140:California; D003362:Cost-Benefit Analysis; D003661:Decision Support Techniques; D000077542:Eptifibatide; D005260:Female; D006745:Hospital Bed Capacity, 300 to 499; D006764:Hospitals, Community; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D002546:Ischemic Attack, Transient / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D000077542:Eptifibatide; D000077284:Abciximab